

AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims

1-63. Canceled

64. (Currently amended) A bispecific antibody ~~with binding specificity for a first epitope and a second epitope wherein the first epitope is the epitope of a mammalian dipeptidyl peptidase IV recognized by E19 and E26~~ comprising an antigen binding portion of monoclonal antibody E19 (ATCC PTA-3378) or E26 (ATCC PTA-3377) that specifically binds to an epitope of a mammalian dipeptidyl peptidase IV, and an antigen binding portion of an antibody that specifically binds to a second epitope.

65. (Previously presented) A bispecific antibody according to claim 64, wherein the second epitope is an epitope of seprase, an epitope of MT1-MMP, an epitope of MMP-2 or an epitope of $\alpha(3)\beta(1)$ -integrin.

66. (Currently amended) A bispecific antibody ~~with binding specificity for a first epitope and a second epitope wherein the first epitope is the epitope of a mammalian dipeptidyl peptidase IV recognized by E19 and E26~~ comprising an antigen binding portion of monoclonal antibody E19 (ATCC PTA-3378) or E26 (ATCC PTA-3377) that specifically binds to an epitope of a mammalian dipeptidyl peptidase IV, and an antigen binding portion of an antibody that specifically binds to a second epitope, wherein the bispecific antibody inhibits cancer invasion.

67. (Previously presented) A bispecific antibody according to claim 66, wherein the second epitope is an epitope of seprase, an epitope of MT1-MMP, an epitope of MMP-2 or an epitope of $\alpha(3)\beta(1)$ -integrin.

68. (Currently amended) A bispecific antibody ~~with binding specificity for a first epitope and a second epitope wherein the first epitope is the epitope of a mammalian dipeptidyl peptidase IV recognized by E19 and E26 comprising an antigen binding portion of~~ monoclonal antibody E19 (ATCC PTA-3378) or E26 (ATCC PTA-3377) that specifically binds to an epitope of a mammalian dipeptidyl peptidase IV, and an antigen binding portion of an antibody that specifically binds to a second epitope, wherein the bispecific antibody inhibits cancer metastasis.
69. (Previously presented) A bispecific antibody according to claim 68, wherein the second epitope is an epitope of seprase, an epitope of MT1-MMP, an epitope of MMP-2 or an epitope of $\alpha(3)\beta(1)$ -integrin.
70. (Previously presented) A composition for inhibiting angiogenesis comprising an effective amount of a bispecific antibody according to claim 64 and a pharmaceutically acceptable carrier.
71. (Previously presented) A composition for inhibiting cancer invasion comprising an effective amount of a bispecific antibody according to claim 66 and a pharmaceutically acceptable carrier.
72. (Previously presented) A composition for inhibiting cancer metastasis comprising an effective amount of a bispecific antibody according to claim 68 and a pharmaceutically acceptable carrier.